(0.61-6.58) Breast C50 451 441 10 0.84 (0.45-1.57) 0.83 (0.44-1.57) 0.93 (0.44-1.98) Uterus Cervix C53 133 131 2 0.60 (0.15-2.43) 0.61 (0.15-2.48) 0.66 (0.09-4.83) Corpus C54 89 85 4 1.82 (0.66-4.99) 1.68 (0.61-4.64) 1.30 (0.31-5.38) Ovary C56 74 69 5 2.49 (...
Cancer outcomes were coded according to ICD-9 and ICD-10 as follows: melanoma (ICD-10: C43; ICD-9: 172), oropharyngeal cancers (ICD-10: C00-C14; ICD-9: 140–149), lung (ICD-10: C33-C34; ICD-9: 162), breast: female only (ICD-10: C50; ICD-9: 174), uterus (ICD-10: C54...
between sex hormone-binding globulin (SHBG) and the risk of FGT polyps (rg = -0,21, se = 0.04, P = 2.9 x 10-6), and on the phenotypic level (PheWAS), the strongest associations were observed with endometriosis, leiomyoma of the uterus and excessive, frequent and irregular menstruation....
Endometriosis is a chronic, multifactorial gynecological disorder affecting approximately 10% of women of reproductive age worldwide, leading to debilitating symptoms such as chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility.Citation1,Citation2Despite its high prevalence, the pathogenesis of end...
For breast, uterus, and ovarian cancer outcomes, we additionally included in Model 2: baseline menopausal status, use of oral contraceptives, use of hormone replacement therapy, and parity. We performed separate Cox regression for each measurement of UPF consumption: continuous per 10% absolute ...